Efficacy of Chemotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer Patients - Do Homologous Recombination Deficiency Affect the Outcomes?

Yekeduz E., UTKAN G., ÜRÜN Y.

UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, cilt.19, sa.4, ss.175-176, 2020 (ESCI) identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 19 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4274/uob.galenos.2020.1555
  • Dergi Adı: UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.175-176
  • Anahtar Kelimeler: Chemotherapy, homologous-recombination deficiency, prostate cancer, PLATINUM-BASED CHEMOTHERAPY, AGGRESSIVE VARIANTS
  • Ankara Üniversitesi Adresli: Evet

Özet

Homologous recombination (HR) is a major repair mechanism of DNA damage. Platin-based agents are known to be more effective in patients with impaired HR mechanism. Previous studies combined platin compounds with docetaxel, but most of these studies did not perform subgroup analysis for HR-deficient patients. Aggressive variant prostate cancer (AVPC) is considered more susceptible to carboplatin. Furthermore, prostate cancers with a higher rate of small cell or anaplastic carcinoma components are more susceptible to carboplatin plus etoposide. We thought that the effect of cabazitaxel plus carboplatin on the progression-free survival might be related to carboplatin alone. In a study that evaluated the effect of cabazitaxel plus carboplatin, the proportion of AVPC patients was higher in the combination group than in the cabazitaxel group. Additionally, the combination of cabazitaxel and carboplatin led to increased toxicity.